Tirzepatide and cardiovascular outcomes

BMJ · Published 2026-08-05 · DOI 10.1136/bmj-2026-100366

Authors (3)

Sourbha S Dani, Arjun Jayakumar, Sarju Ganatra

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Dani, S., Jayakumar, A., Ganatra, S. (2026). Tirzepatide and cardiovascular outcomes. BMJ. https://doi.org/10.1136/bmj-2026-100366

Related articles

• Tirzepatide and the risk of atherosclerotic cardiovascular events: population based cohort study · BMJ · 2026 · Cites or is cited by this article · Same journal
• Medical colleges developing successor to axed NHS training scheme for overseas doctors · BMJ · 2026 · Same journal
• Does Mounjaro cause hair loss? · BMJ · 2026 · Same journal
• Palantir tool has not cut delayed discharges at NHS trusts, study finds · BMJ · 2026 · Same journal
• Brain gain, waste, strain, and drain: international medical graduates after UK medical training legislation · BMJ · 2026 · Same journal
• Four fifths of NHS trusts are still using pen and paper for record keeping, 25 years after first digitisation push · BMJ · 2026 · Same journal
• Comparative effectiveness of azithromycin versus roflumilast in patients with chronic obstructive pulmonary disease: emulated target trial · BMJ · 2026 · Same journal
• Ectopic pregnancy: Rise in admissions may be linked to deprivation, study suggests · BMJ · 2026 · Same journal
• Fossil fuel industry has no place at climate COP · BMJ · 2026 · Same journal
• Private equity involvement in UK healthcare · BMJ · 2026 · Same journal